{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:28:53Z","timestamp":1790346533029,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA230319, P30CA240139"],"award-info":[{"award-number":["K08CA230319, P30CA240139"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","award":["DRG"],"award-info":[{"award-number":["DRG"]}],"id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["CSDA"],"award-info":[{"award-number":["CSDA"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Olutasidenib is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) that was recently approved by the US FDA for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring mutant IDH1. In the pivotal Phase II trial of olutasidenib, the median duration of complete response (CR) was 28.1 months. Here we report the first patient in the world to receive olutasidenib, for relapsed NPM1 and IDH1 co-mutated AML, who remains in continuous CR for over 7 years on olutasidenib monotherapy. We detail the clinical course as well as the pathologic and genomic evolution of the disease. Furthermore, using a novel single cell measurable residual disease assay and digital PCR and qPCR for the detection of IDH1 and NPM1 mutations, we found no evidence of residual detectable leukemia. To our knowledge, this is the first report of an AML patient functionally cured by IDH1 inhibitor monotherapy.<\/jats:p>","DOI":"10.1038\/s41698-025-01013-5","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:15:40Z","timestamp":1751372140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Functional cure with single agent olutasidenib in relapsed IDH1\/NPM1 co-mutated AML"],"prefix":"10.1038","volume":"9","author":[{"given":"Justin","family":"Watts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Micin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Madarang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Affer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shefali","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Alvarez","family":"Lesmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulasigeri","family":"Totiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Swords","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"1013_CR1","first-page":"165","volume":"97","author":"T Naoe","year":"2013","unstructured":"Naoe, T. & Kiyoi, H. Gene mutations of acute myeloid leukemia in the genome era. Hematology 97, 165\u2013174 (2013).","journal-title":"Hematology"},{"key":"1013_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ajh.24252","volume":"91","author":"CD DiNardo","year":"2016","unstructured":"DiNardo, C. D. et al. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am. J. Hematol. 91, 227\u2013232 (2016).","journal-title":"Am. J. Hematol."},{"key":"1013_CR3","unstructured":"Cancer Stat Facts: Leukemia\u2014Acute Myeloid Leukemia (AML): National Cancer Institute Surveillance, Epidemiology, and End Results Program; (2023)."},{"key":"1013_CR4","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","volume":"100","author":"JC Byrd","year":"2002","unstructured":"Byrd, J. C. et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100, 4325\u20134336 (2002).","journal-title":"Blood"},{"key":"1013_CR5","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","volume":"98","author":"D Grimwade","year":"2001","unstructured":"Grimwade, D. et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98, 1312\u20131320 (2001).","journal-title":"Blood"},{"key":"1013_CR6","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","volume":"96","author":"ML Slovak","year":"2000","unstructured":"Slovak, M. L. et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study. Blood 96, 4075\u20134083 (2000).","journal-title":"Blood"},{"key":"1013_CR7","first-page":"2322","volume":"92","author":"D Grimwade","year":"1998","unstructured":"Grimwade, D. et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Med. Res. Counc. Adult Children\u2019s Leuk. Working Parties Blood 92, 2322\u20132333 (1998).","journal-title":"Med. Res. Counc. Adult Children\u2019s Leuk. Working Parties Blood"},{"key":"1013_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.beha.2012.10.002","volume":"25","author":"DC Link","year":"2012","unstructured":"Link, D. C. Molecular genetics of AML. Best. Pr. Res Clin. Haematol. 25, 409\u2013414 (2012).","journal-title":"Best. Pr. Res Clin. Haematol."},{"key":"1013_CR9","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.3390\/cancers12113225","volume":"12","author":"M Stanchina","year":"2020","unstructured":"Stanchina, M., Soong, D., Zheng-Lin, B., Watts, J. M. & Taylor, J. Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development. Cancers (Basel) 12, 3225 (2020).","journal-title":"Cancers (Basel)"},{"key":"1013_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00497-1","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa, G. C. & DiNardo, C. D. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. Blood Cancer J. 11, 107 (2021).","journal-title":"Blood Cancer J."},{"key":"1013_CR11","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1097\/HS9.0000000000000583","volume":"5","author":"BJ Wouters","year":"2021","unstructured":"Wouters, B. J. Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions. Hemasphere 5, e583 (2021).","journal-title":"Hemasphere"},{"key":"1013_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","volume":"18","author":"CJ Pirozzi","year":"2021","unstructured":"Pirozzi, C. J. & Yan, H. The implications of IDH mutations for cancer development and therapy. Nat. Rev. Clin. Oncol. 18, 645\u2013661 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1013_CR13","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1074\/jbc.M112.435495","volume":"288","author":"PS Ward","year":"2013","unstructured":"Ward, P. S. et al. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J. Biol. Chem. 288, 3804\u20133815 (2013).","journal-title":"J. Biol. Chem."},{"key":"1013_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739\u2013744 (2009).","journal-title":"Nature"},{"key":"1013_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel, J. P. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med 366, 1079\u20131089 (2012).","journal-title":"N. Engl. J. Med"},{"key":"1013_CR16","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl. J. Med 374, 2209\u20132221 (2016).","journal-title":"N. Engl. J. Med"},{"key":"1013_CR17","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","volume":"28","author":"P Paschka","year":"2010","unstructured":"Paschka, P. et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J. Clin. Oncol. 28, 3636\u20133643 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1013_CR18","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea, D. A. et al. Impact of Venetoclax and Azacitidine in Treatment-Na\u00efve Patients with Acute Myeloid Leukemia and IDH1\/2 Mutations. Clin. Cancer Res 28, 2753\u20132761 (2022).","journal-title":"Clin. Cancer Res"},{"key":"1013_CR19","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute Myeloid Leukemia. N. Engl. J. Med 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med"},{"key":"1013_CR20","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1182\/blood-2010-05-260117","volume":"116","author":"JM Rowe","year":"2010","unstructured":"Rowe, J. M. & Tallman, M. S. How I treat acute myeloid leukemia. Blood 116, 3147\u20133156 (2010).","journal-title":"Blood"},{"key":"1013_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"1013_CR22","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo, C. D. et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N. Engl. J. Med 378, 2386\u20132398 (2018).","journal-title":"N. Engl. J. Med"},{"key":"1013_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood.2019002140","volume":"135","author":"GJ Roboz","year":"2020","unstructured":"Roboz, G. J. et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood 135, 463\u2013471 (2020).","journal-title":"Blood"},{"key":"1013_CR24","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","volume":"4","author":"S Choe","year":"2020","unstructured":"Choe, S. et al. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 4, 1894\u20131905 (2020).","journal-title":"Blood Adv."},{"key":"1013_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.931462","volume":"12","author":"X Zhuang","year":"2022","unstructured":"Zhuang, X. et al. The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia. Front Oncol. 12, 931462 (2022).","journal-title":"Front Oncol."},{"key":"1013_CR26","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","volume":"7","author":"S de Botton","year":"2023","unstructured":"de Botton, S. et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 7, 3117\u20133127 (2023).","journal-title":"Blood Adv."},{"key":"1013_CR27","doi-asserted-by":"crossref","unstructured":"Cortes, J. E. et al. Olutasidenib For Mutated IDH1 Acute Myeloid Leukemia: Final Five-Year Results From The Phase 2 Pivotal Cohort. JCO. 42, 6528 (2024).","DOI":"10.1200\/JCO.2024.42.16_suppl.6528"},{"key":"1013_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/17474086.2016.1107471","volume":"9","author":"C Lai","year":"2016","unstructured":"Lai, C., Karp, J. E. & Hourigan, C. S. Precision medicine for acute myeloid leukemia. Expert Rev. Hematol. 9, 1\u20133 (2016).","journal-title":"Expert Rev. Hematol."},{"key":"1013_CR29","doi-asserted-by":"crossref","unstructured":"Totiger, T. M. et al. Targeted Therapy Development in Acute Myeloid Leukemia. Biomedicines. 11, 641 (2023).","DOI":"10.3390\/biomedicines11020641"},{"key":"1013_CR30","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1182\/bloodadvances.2023009854","volume":"7","author":"S Venugopal","year":"2023","unstructured":"Venugopal, S. & Watts, J. Olutasidenib: from bench to bedside. Blood Adv. 7, 4358\u20134365 (2023).","journal-title":"Blood Adv."},{"key":"1013_CR31","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1021\/acs.jmedchem.9b01423","volume":"63","author":"JA Caravella","year":"2020","unstructured":"Caravella, J. A. et al. Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor. J. Med Chem. 63, 1612\u20131623 (2020).","journal-title":"J. Med Chem."},{"key":"1013_CR32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"1013_CR33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jmoldx.2018.03.005","volume":"20","author":"AG Selim","year":"2018","unstructured":"Selim, A. G. & Moore, A. S. Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions. J. Mol. Diagn. 20, 389\u2013397 (2018).","journal-title":"J. Mol. Diagn."},{"key":"1013_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg0488","volume":"9","author":"TM Robinson","year":"2023","unstructured":"Robinson, T. M. et al. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Sci. Adv. 9, eadg0488 (2023).","journal-title":"Sci. Adv."},{"key":"1013_CR35","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1182\/blood-2023-187584","volume":"142","author":"E Wang","year":"2023","unstructured":"Wang, E. et al. Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia. Blood 142, 6047 (2023).","journal-title":"Blood"},{"key":"1013_CR36","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1182\/blood-2021-144912","volume":"138","author":"S De Botton","year":"2021","unstructured":"De Botton, S. et al. Molecular characteristics of response to olutasidenib (FT-2102) in patients with relapsed\/refractory mIDH1 acute myeloid leukemia. Blood 138, 2351 (2021).","journal-title":"Blood"},{"key":"1013_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-022-01339-8","volume":"15","author":"D Kunadt","year":"2022","unstructured":"Kunadt, D. et al. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation. J. Hematol. Oncol. 15, 126 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"1013_CR38","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1182\/blood.2024024310","volume":"144","author":"J Othman","year":"2024","unstructured":"Othman, J. et al. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML. Blood 144, 714\u2013728 (2024).","journal-title":"Blood"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01013-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01013-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01013-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:15:42Z","timestamp":1751372142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01013-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1013"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01013-5","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.W.: advisory board\/consultancy: Servier, Rigel, BMS, Aptose, Daiichi Sankyo, Ativarre. Research support: Takeda, Rigel, Immune Systems Key, Ltd. A.T. is now an employee at Rigel Pharmaceuticals, Inc. T.T.: advisory board\/consultancy: Morphosys, Novartis. Advisory: Sobi, Servier. DSMB: Karyopharm. R.S.: consultancy: Rigel, Abbvie. T.N., K.M., D.S., E.M., M.A., S.M., J.A.L., J.C., Y.Z., T.B., J.T.: Nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}